Sachs 5th Annual North American Forum: Investing & Partnering in Biotech Presenter Profile for NOXXON Pharma AG.BOSTON Boston, town, England Boston, town (1991 pop. 26,495), E central England, on the Witham River. Boston's fame as a port dates from the 13th cent., when it was a Hanseatic port trading wool and wine. Having recovered from a decline in the 18th and 19th cent. -- Sachs Sachs , Hans 1494-1576. German writer and Meistersinger noted for his many dramas, poems, and songs. His life inspired Wagner's opera Die Meistersinger von Nürnberg (1868). Associates 5th Annual North American Forum The North American Forum is an annual meeting of U.S., Canadian and Mexican government and business representatives to discuss issues related to continental economic and social integration. The Forum is chaired jointly by former U.S. : Investing & Partnering in Biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. takes place Mar. 13-14, 2006, at The Fairmont Fairmont, city (1990 pop. 20,210), seat of Marion co., N central W.Va., where the West Fork and Tygart rivers form the Monongahela; settled 1793 around Prickett's Fort (1774), inc. as Fairmont 1843. Copley Plaza The Fairmont Copley Plaza hotel (or Copley Plaza as it is colloquially known) is a four-star hotel in downtown Boston, Massachusetts. It was built in 1912 on St. James Avenue and defines the south side of Copley Square. The Copley Plaza Hotel opened in 1912. in Boston. For in-depth in-depth adj. Detailed; thorough: an in-depth study. in-depth Adjective detailed or thorough: an in-depth analysis information about the event, visit http://www.sachsforum.com/boston06.html Business Wire is the official news wire service for 5th Annual North American Forum: Investing & Partnering in Biotech. Below is NOXXON Pharma AG's presenter profile. News releases and advisories are available at http://www.tradeshownews.com, Business Wire's trade show, conference, and event news resource. Company: NOXXON Pharma AG Investor Relations Contact: Thomas Klein, CEO Investor Relations Contact Phone: +49 30 726 247 100 Web: www.noxxon.net Date of Presentation: March 14, 2006 Time of Presentation: 14:25 - 14:40 Company description: NOXXON Pharma AG focuses on the rapid discovery and development of innovative pharmaceuticals in high demand disease indications. Based on its vast intellectual property estate of over 340 patents and patent applications, NOXXON generates Spiegelmers(TM), high potency RNA therapeutics that inactivate disease targets with exquisite specificity. Unlike regular RNA, Spiegelmers(TM) are extremely biostable -- the next generation aptamer therapeutics. NOXXON is building its own drug pipeline and will enter clinical trials in early 2007 with Spiegelmers(TM) for inflammatory and neovascular disorders. The Company intends to finance the initial stages of clinical trials through phase II and seeks funding for this purpose. In addition to its own development activities, NOXXON exploits the strengths of its technology through licensing of products to partners for further development as well as through drug discovery partnerships. NOXXON expects to complete a multi-year strategic licensing and collaborative research agreement with a major pharmaceutical company at the end of Q1 of this year. Note to Editors: Business Wire's PressPass allows you to create free, custom Web, RSS (Really Simple Syndication) A syndication format that was developed by Netscape in 1999 and became very popular for aggregating updates to blogs and the news sites. RSS has also stood for "Rich Site Summary" and "RDF Site Summary. , and email-based news feeds from more than 160 industry options, dozens of subject categories and thousands of geographic preferences as well as by specific company filters. In addition, PressPass subscribers have access to exclusive content to experts, company profiles, email alerts, survey services and other media services. Note to Event Organizers: Add your trade show, conference, or event to www.tradeshownews.com, Business Wire's online event calendar. For information, email tradeshow@businesswire.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion